Novo Nordisk Unusual Options Activity For November 19
Novo Nordisk Unusual Options Activity For November 19
From the overall spotted trades, 11 are puts, for a total amount of $549,674 and 34, calls, for a total amount of $2,045,493.Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk.
有很多資金要花費的大鯨魚明顯看好諾和諾德。
Looking at options history for Novo Nordisk (NYSE:NVO) we detected 45 trades.
查看Novo Nordisk（紐交所:NVO）的期權歷史，我們發現了45筆交易。
If we consider the specifics of each trade, it is accurate to state that 57% of the investors opened trades with bullish expectations and 40% with bearish.
如果我們考慮每筆交易的具體情況，可以準確地說，57%的投資者以看好的預期開盤交易，40%的投資者以看淡的預期開盤交易。
From the overall spotted trades, 11 are puts, for a total amount of $549,674 and 34, calls, for a total amount of $2,045,493.
從整體發現的交易中，有11筆是看跌期權，總金額爲$549,674，34筆是看漲期權，總金額爲$2,045,493。
Projected Price Targets
預計價格目標
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $70.0 to $130.0 for Novo Nordisk during the past quarter.
分析這些合約的成交量和未平倉合約，似乎大玩家在過去一個季度內一直關注Novo Nordisk的價格區間在$70.0到$130.0之間。
Analyzing Volume & Open Interest
分析成交量和未平倉合約
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Novo Nordisk's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Novo Nordisk's whale trades within a strike price range from $70.0 to $130.0 in the last 30 days.
查看成交量和未平倉合約是期權交易中的一種強大工具。此數據可以幫助您跟蹤Novo Nordisk在給定行權價的期權的流動性和興趣。以下，我們可以觀察Novo Nordisk在過去30天內，所有鯨魚交易的看漲和看跌期權的成交量和未平倉合約的演變，行權價區間爲$70.0到$130.0。
Novo Nordisk Option Activity Analysis: Last 30 Days
諾和諾德期權活動分析:最近30天
Significant Options Trades Detected:
檢測到重大期權交易：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NVO | CALL | TRADE | BEARISH | 12/20/24 | $2.34 | $2.22 | $2.23 | $115.00 | $289.9K | 11.2K | 3.4K |
| NVO | CALL | SWEEP | BULLISH | 12/20/24 | $5.7 | $5.6 | $5.66 | $105.00 | $190.8K | 2.1K | 557 |
| NVO | CALL | SWEEP | BULLISH | 12/20/24 | $5.7 | $5.6 | $5.7 | $105.00 | $152.7K | 2.1K | 994 |
| NVO | PUT | TRADE | BULLISH | 01/17/25 | $19.05 | $18.8 | $18.8 | $120.00 | $112.8K | 1.9K | 71 |
| NVO | PUT | SWEEP | BEARISH | 01/17/25 | $5.0 | $4.95 | $4.95 | $97.50 | $99.5K | 2.4K | 224 |
| 標的 | 看跌/看漲 | 交易類型 | 情緒 | 到期日 | 賣盤 | 買盤 | 價格 | 執行價格 | 總交易價格 | 未平倉合約數量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NVO | 看漲 | 交易 | 看淡 | 12/20/24 | $2.34 | $2.22 | $2.23 | $115.00 | 289.9千美元 | 11.2K | 3.4千 |
| NVO | 看漲 | SWEEP | BULLISH | 12/20/24 | $5.7 | $5.6 | 5.66美元 | $105.00 | 190.8千美元 | 2.1K | 557 |
| NVO | 看漲 | SWEEP | BULLISH | 12/20/24 | $5.7 | $5.6 | $5.7 | $105.00 | $152.7K | 2.1K | 994 |
| NVO | 看跌 | 交易 | BULLISH | 01/17/25 | $19.05 | $18.8 | $18.8 | $120.00 | $112.8K | 1.9K | 71 |
| NVO | 看跌 | SWEEP | 看淡 | 01/17/25 | $5.0 | $4.95 | $4.95 | $97.50 | 99.5K美元 | 2.4K | 224 |
About Novo Nordisk
諾和諾德是一家領先的全球醫療保健公司，致力於研發創新藥品，幫助患糖尿病的患者過上更長壽、更健康的生活，這一傳統已有100多年。這種傳統爲我們提供了經驗和能力，使我們能夠推動變革，幫助人們戰勝其他嚴重的慢性疾病，如肥胖症、罕見的血液和內分泌紊亂。我們始終堅信，持久的成功公式是保持專注，長遠思考，並以財務、社會和環境負責任的方式做生意。諾和諾德在新澤西州設有美國總部，在7個州加上華盛頓特區擁有商業、生產和研究設施，在全國約有8000名員工。有關更多信息，訪問novonordisk-us.com，Facebook、Instagram和X。
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
作爲全球治療糖尿病品牌市場三分之一的領先者，丹麥的Novo Nordisk公司是世界上提供糖尿病護理產品的主要製造商和市場推廣者。該公司製造和銷售各種人體和現代胰島素、GLP-1療法等可注射糖尿病治療藥物、口服降糖藥以及肥胖症治療藥物。Novo Nordisk還有一個生物製藥部門（約佔營收的10%），專門從事血友病和其他疾病的蛋白質療法。
Having examined the options trading patterns of Novo Nordisk, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
經過對Novo Nordisk的期權交易模式的分析，我們現在將關注點直接轉向公司本身。這個轉變使我們能夠深入探究其當前的市場地位和表現。
Novo Nordisk's Current Market Status
Novo Nordisk的當前市場狀況
- With a trading volume of 4,369,108, the price of NVO is up by 2.64%, reaching $102.44.
- Current RSI values indicate that the stock is may be oversold.
- Next earnings report is scheduled for 71 days from now.
- NVO的成交量爲4,369,108，價格上漲了2.64%，達到了102.44美元。
- 當前RSI指標表明該股可能被超賣。
- 下一個業績將於71天后發佈。
Expert Opinions on Novo Nordisk
諾和諾德專家意見
In the last month, 1 experts released ratings on this stock with an average target price of $160.0.
在過去的一個月裏，有1個專家對這隻股票發佈了評級，平均目標價爲160.0美元。
Unusual Options Activity Detected: Smart Money on the Move
檢測到期權異動：智慧資金在行動。
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access.* In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $160.
Benzinga Edge的期權異動板塊在市場動向發生之前發現潛在的市場推動者。查看大資金在你最喜歡的股票上採取了什麼倉位。點擊這裏獲取訪問權限。* 在一次謹慎的舉動中，來自Cantor Fitzgerald的分析師將其評級下調至增持，設定目標價爲160美元。
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
期權與僅交易股票相比是一種更具風險的資產，但它們具有更高的利潤潛力。認真的期權交易者通過每日學習，進出交易，跟隨多個指標並密切關注市場來管理這種風險。
譯文內容由第三人軟體翻譯。
